Full Press Release Details
REGULATED INFORMATION
MARCH 2, 2023, 4:30 pm ET/ 22:30 CET
MDxHealth Shareholder Transparency Declarations
IRVINE, CA, and HERSTAL, BELGIUM -
March [2], 2023 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company"
or "mdxhealth"), a commercial-stage precision diagnostics company, announces
today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which
shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"),
that it received the following notifications.
The Company was notified that the number of shares
with respect to which MVM Partners, LLC can exercise voting rights passively crossed below the threshold of 20% of the outstanding shares
and voting rights of mdxhealth on February 7, 2023. Notably, it follows from the notification by MVM Partners, LLC, who notified alone,
that an aggregate of 45,504,584 shares of mdxhealth, representing 17.31% of the 262,880,936 outstanding shares and voting rights of mdxhealth,
is held through the following entities: MVM V LP (which owns 1,877,945 American depositary shares ("ADSs") and 25,805,845
shares of mdxhealth) and MVM GP (No. 5) LP (which owns 38,721 ADSs and 532,079 shares of mdxhealth). The notification also stated that
MVM Partners, LLC is not a controlled entity, acts as fund manager of the aforementioned two entities, and can exercise the voting rights
attached to the securities at its own discretion, without specific instruction. Furthermore, it is stated that the fund management of
MVM V LP and MVM GP (No.5) LP was previously done by MVM Partners LLP, but, on July 1, 2022, MVM Partners LLC replaced MVM Partners, LLP
as fund manager of MVM V LP and MVM GP (No.5) LP.
The Company was notified that the number of shares
with respect to which Biovest NV can exercise voting rights passively crossed below the threshold of 5% of the outstanding shares and
voting rights of mdxhealth on February 7, 2023. Notably, it follows from the notification by Biovest NV that 11,923,587 shares of mdxhealth,
representing 4.54% of the 262,880,936 outstanding shares and voting rights of mdxhealth, are held through Biovest NV. The notification
also stated that Biovest NV is for 100% owned by RMM S.A., which is ultimately held by Sniper Invest S.A. (ultimately owned by Stefan
Mari n), Fontana Invest S.A. (ultimately owned by Frederic Mari n) and Radium Invest S.A. (ultimately owned by Robin Devos),
each for a third, that Biovest NV did not participate to the capital increase of 7 February 2023, that Stefan Mari n was appointed
as director of Sniper Invest S.A. on 22 September 2021, that Frederic Mari n was appointed as director of Fontana Invest S.A. on
22 September 2021, that Robin Devos was appointed as director of Radium Invest S.A. on 22 September 2021, ant that, accordingly, control
of the mdxhealth stake held by Biovest NV (11,923,587 shares) was passed in full from Rudi Mari n to Stefan Mari n, Frederic
Mari n and Robin Devos.
For further information, reference is made to
the information published on mdxhealth's website (http://www.mdxhealth.com/investors/shareholder-information).
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA)
is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such
persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total
number of voting rights in the Company.
mdxhealth is a commercial-stage precision diagnostics
company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based
on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis
of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California,
with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen,
facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of
MDxHealth SA. All other trademarks and service marks are the property of their respective owners.